Ensysce Biosciences heads into its May 20 earnings report with an unusually charged lending market — the defining feature of its current setup.
The borrow story here is striking. Cost to borrow has risen to 122.7% annualised, up 61% over the past week alone, after touching a peak of 234.8% on May 14. That kind of borrowing expense signals intense demand for short exposure in a stock that had virtually no short interest just two weeks ago. As recently as May 8, SI was below 0.5% of the free float. By May 12 it had exploded to over 7%, before easing back to 4.3% by May 15 — still nearly ten times the level from ten days prior. Availability, at 126%, has loosened significantly from the sub-30% readings seen mid-week, suggesting the acute squeeze on the lending pool has partially resolved, but borrow remains expensive.
The ORTEX short score reflects how fast the landscape shifted. It jumped from roughly 41 on May 7 to a peak of 72.4 on May 13, before pulling back to 64.9 by May 15. That score places ENSC in elevated short-pressure territory, even after the partial unwind. The DTC percentile rank (88th) confirms that relative to its history, the stock is carrying significant days-to-cover pressure. The stock itself has paid the price: down 46% over the past month and 20% on the week, closing at $0.28 on May 15, even as peers like and shed a more modest 6% and 4% respectively over the same period — underscoring that the selling in ENSC has been company-specific, not a broad micro-biotech drag.
There is little current analyst or valuation data available to frame the fundamental debate. Insider data is stale (last recorded trades date to early 2023), and options data is similarly outdated at over 1,300 days old. The absence of fresh sell-side coverage leaves the setup almost entirely defined by the technical and lending dynamics rather than any fundamental catalyst — which itself sharpens the stakes of the print.
The earnings release will test whether the recent burst of short selling reflects genuine concern about the company's financial position, or whether it was tactical positioning that the announcement itself quickly unwinds.
See the live data behind this article on ORTEX.
Open ENSC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
